OraSure Technologies, Inc. (OSUR) Downgraded by Zacks Investment Research to “Hold”
OraSure Technologies, Inc. (NASDAQ:OSUR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians’ offices, and workplace sites. “
Several other research firms have also recently weighed in on OSUR. Stephens reissued an “overweight” rating and set a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. BidaskClub lowered OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 price objective on shares of OraSure Technologies in a report on Tuesday, September 19th. Finally, Jefferies Group LLC upped their price objective on OraSure Technologies from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, June 28th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $18.04.
OraSure Technologies (NASDAQ OSUR) opened at 22.77 on Wednesday. OraSure Technologies has a 52-week low of $7.09 and a 52-week high of $22.99. The company has a market capitalization of $1.35 billion, a P/E ratio of 42.09 and a beta of 1.55. The stock’s 50 day moving average is $21.34 and its 200-day moving average is $16.97.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. The firm had revenue of $40.18 million during the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.07 earnings per share. Analysts predict that OraSure Technologies will post $0.48 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “OraSure Technologies, Inc. (OSUR) Downgraded by Zacks Investment Research to “Hold”” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/orasure-technologies-inc-osur-downgraded-by-zacks-investment-research-to-hold/1607171.html.
In other news, CFO Ronald H. Spair sold 510,112 shares of OraSure Technologies stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the transaction, the chief financial officer now directly owns 208,606 shares of the company’s stock, valued at approximately $4,309,799.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Douglas A. Michels sold 25,000 shares of OraSure Technologies stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $22.55, for a total value of $563,750.00. Following the transaction, the chief executive officer now directly owns 743,058 shares in the company, valued at $16,755,957.90. The disclosure for this sale can be found here. Insiders have sold 694,678 shares of company stock worth $14,450,169 over the last quarter. 6.40% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in OSUR. BlackRock Inc. increased its holdings in OraSure Technologies by 127,593.4% in the 1st quarter. BlackRock Inc. now owns 7,743,325 shares of the medical instruments supplier’s stock worth $100,123,000 after acquiring an additional 7,737,261 shares in the last quarter. Daruma Capital Management LLC lifted its holdings in OraSure Technologies by 2,761.0% during the second quarter. Daruma Capital Management LLC now owns 2,821,506 shares of the medical instruments supplier’s stock valued at $48,699,000 after purchasing an additional 2,722,886 shares in the last quarter. Vanguard Group Inc. lifted its holdings in OraSure Technologies by 30.3% during the first quarter. Vanguard Group Inc. now owns 4,466,499 shares of the medical instruments supplier’s stock valued at $57,752,000 after purchasing an additional 1,037,439 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in OraSure Technologies by 22.3% during the first quarter. Renaissance Technologies LLC now owns 5,132,003 shares of the medical instruments supplier’s stock valued at $66,357,000 after purchasing an additional 934,700 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in OraSure Technologies by 127.2% during the first quarter. JPMorgan Chase & Co. now owns 1,573,586 shares of the medical instruments supplier’s stock valued at $20,347,000 after purchasing an additional 881,132 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.